M&A Deal Summary

Montagu Acquires Resolve Surgical Technologies

On January 4, 2022, private equity firm Montagu acquired medical products company Resolve Surgical Technologies from Surgalign

Acquisition Highlights
  • This is Montagu’s 9th transaction in the Medical Products sector.
  • This is Montagu’s 3rd transaction in the United States.
  • This is Montagu’s 1st transaction in Michigan.

M&A Deal Summary
Date 2022-01-04
Target Resolve Surgical Technologies
Sector Medical Products
Buyer(s) Montagu
Sellers(s) Surgalign
Deal Type Buyout (LBO, MBO, MBI)

Target

Resolve Surgical Technologies

Marquette, Michigan, United States
Resolve Surgical Technologies is a designer and private label manufacturer of metal implants and instruments used in Trauma, Spine, and Extremities surgeries. Resolve Surgical Technologies is based in Marquette, Michigan.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Montagu

London, United Kingdom

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1968
PE ASSETS 11.0B EUR
Size Mega
Type Sector Agnostic
DESCRIPTION

Montagu is an independent private equity firm focused on European management buyouts and growth capital transactions. The Firm seeks opportunities valued between €100 million and €1 billion. Sectors of interest include healthcare, medical products, financial services, software, IT, information services, and education. Montagu dates back to 1968 and is based in London.

DEAL STATS #
Overall 111 of 115
Sector (Medical Products) 9 of 10
Type (Buyout (LBO, MBO, MBI)) 59 of 59
State (Michigan) 1 of 1
Country (United States) 3 of 5
Year (2022) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-12 HTL Biotechnology

Javene, France

HTL Biotechnology is a fast-growing biotech and industrial firm leading the development and production of innovative pharmaceutical-grade biopolymers. The company has developed a state-of-the-art biopolymers platform that provides customized, pharmaceutical-grade biopolymer solutions to leading pharmaceutical and medical device companies worldwide. Its products are used in therapeutic areas such as ophthalmology, rheumatology, urology, dermatology, and medical aesthetics. HTL Biotechnology was formed in 1992 and is based in Javene, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-07-19 EPFR

Boston, Massachusetts, United States

EPFR’s Flows and Allocations data provides a unique view of the investor and fund manager sentiment across global markets, helping buy and sell-side institutions make informed decisions. EPFR was formed in 1995 and is based in Boston, Massachusetts.

Buy -

Seller(S) 1

SELLER

Surgalign

Deerfield, Illinois, United States
Category Company
Founded 1997
Sector Medical Products
Employees200
Revenue 102M USD (2020)
DESCRIPTION

Surgalign is a medical technology company focused on advancing spine surgery including through the application of digital technologies to improve patient outcomes. The company is building off a legacy of high quality and differentiated products and continues to invest in clinically validated innovation to deliver better surgical outcomes and improve patient’s lives. Surgalign markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. Surgalign was formed in 1997 and is based in Deerfield, Illinois.

DEAL STATS #
Overall 3 of 4
Sector (Medical Products) 3 of 4
Type (Buyout (LBO, MBO, MBI)) 1 of 1
State (Michigan) 1 of 1
Country (United States) 3 of 4
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-29 HoloSurgical

Chicago, Illinois, United States

Holosurgical is a digital surgery company focused on improving patient outcomes by bringing Augmented Reality and Artificial Intelligence to the operating room. It was founded in 2015 by virtual and augmented reality expert Prof. Cristian Luciano, Ph.D., and spine surgeon Dr. Kris Siemionow, MD, Ph.D., and in 2016 joined by Prof. Paul Lewicki, Ph.D., a pioneer in artificial intelligence.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-03-01 Surgalign s Coflex Product Line

Deerfield, Illinois, United States

Surgalign's Coflex Product Line comprises interlaminar stabilization device used after an open decompression that can be performed in various settings, offering a non-fusion treatment option for lumbar spinal stenosis (LSS) patients. The number of patients diagnosed globally with LSS is approximately 2.4 million representing the largest single-growing patient demographic in spine. The Coflex device is the only FDA PMA-approved implant for the treatment of LSS, has been implanted in more than 200,000 patients in over 60 countries, is clinically validated with more than 90 peer reviewed publications and has established Ambulatory Surgery Center (ASC) reimbursement. Cofix is a supplemental fixation device, which is a minimally invasive system intended for use on all levels of the lumbar spine.

Sell $17M
Mergr

Product

Company

Legal